The variation is due to trade vernacular. The broad category is defining patients with the HLA-A2 serotype also written as HLA-A2+ or maybe even sometimes HLA-2+ of which there are different alleles. HLA-1*0201 is one specific allele. Does this inclusion criteria have more to do with the gp100 vaccine than with ipilimumab?